Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis.

ABSTRACT: A major challenge for successful immunotherapy against glioma is the identification and characterization of validated targets. We have taken a bioinformatics approach towards understanding the biological context of IL-13 receptor α2 (IL13Rα2) expression in brain tumors, and its functional significance for patient survival. Querying multiple gene expression databases, we show that IL13Rα2 expression increases with glioma malignancy grade, and expression for high-grade tumors is bimodal, with approximately 58% of WHO grade IV gliomas over-expressing this receptor. By several measures, IL13Rα2 expression in patient samples and low-passage primary glioma lines most consistently correlates with the expression of signature genes defining mesenchymal subclass tumors and negatively correlates with

SUBMITTER: Brown CE 

PROVIDER: S-EPMC3800130 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature